Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types

SIMPLE SUMMARY: Our study evaluated the use of the intestinal microbiome as a prognostic marker that seems to modulate response to immune checkpoint inhibitor (ICI) treatment in patients with late-stage non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and metastatic melanoma. BiomeOne...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Irina, Hochmair, Maximilian Johannes, Schmidinger, Manuela, Absenger, Gudrun, Pichler, Martin, Nguyen, Van Anh, Richtig, Erika, Rainer, Barbara Margaretha, Ay, Leyla, Jansen, Christian, Pacífico, Cátia, Knabl, Alexander, Sladek, Barbara, Gasche, Nikolaus, Valipour, Arschang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339964/
https://www.ncbi.nlm.nih.gov/pubmed/37444378
http://dx.doi.org/10.3390/cancers15133268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339964/
https://www.ncbi.nlm.nih.gov/pubmed/37444378
http://dx.doi.org/10.3390/cancers15133268

Ejemplares similares